Xue J, et al. - For gastric cancer (GC), hepatocellular carcinoma (HCC) and non-small-cell lung cancer (NSCLC) researchers assessed the short-term effectiveness and safety of apatinib vs combination therapy. In addition, they discussed its anti-angiogenesis therapy applications. Seven clinical studies met the inclusion criteria. The analysis indicated higher success in treating cancers by using apatinib vs therapy without apatinib. The apatinib group showed significant improvement in both objective response rates (ORRs) and disease control rates (DCRs) vs the control group; it also prolonged patient survival. The findings suggest apatinib as beneficial in terms of certain short-term effects and survival in GC, HCC, and NSCLC with controllable adverse effects.